Get the Stockscreener App
57.94
2.49%
1.41
After Hours:
57.94
Astrana Health Inc stock is traded at $57.94, with a volume of 244.26K.
It is up +2.49% in the last 24 hours and up +21.24% over the past month.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. Its operating segment is the healthcare delivery segment.
See More
Previous Close:
$56.53
Open:
$56.36
24h Volume:
244.26K
Relative Volume:
1.02
Market Cap:
$2.58B
Revenue:
$1.45B
Net Income/Loss:
$62.42M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$52.44M
1W Performance:
+1.60%
1M Performance:
+21.24%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$56.36
$57.94
1-Week Range:
$55.34
$57.94
52-Week Range:
$34.91
$58.77
Astrana Health Inc Stock (ASTH) Company Profile
Name
Astrana Health Inc
Sector
Industry
Phone
(626) 282-0288
Address
1668 S. GARFIELD AVENUE, ALHAMBRA
Astrana Health Inc Stock (ASTH) Latest News
Be Wary Of Astrana Health (NASDAQ:ASTH) And Its Returns On Capital - Yahoo Finance
Ascential Shareholding Shifts with Societe Generale’s Move - TipRanks
Magnetar Financial LLC Buys Shares of 20,305 Astera Labs, Inc. (NASDAQ:ALAB) - Defense World
Views of Wall Street’s Leading Experts on Astera Labs Inc. - SETE News
Prospects for datopotamab deruxtecan dented by update - The Pharma Letter
AstraZeneca shares rally 13%, hit record high as firm gets nod for cancer drug Durvalumab - CNBCTV18
Astera Labs, Inc. (NASDAQ:ALAB) Shares Sold by American Century Companies Inc. - Defense World
AstraZeneca Pharma gets nod to sell immunotherapy drug Durvalumab; stock surges - Fortune India
AstraZeneca Pharma shares rally 13%, hit 52-week high after receiving nod for cancer drug Durvalumab - The Economic Times
AstraZeneca Pharma Shares Surge 12% After Approval to Launch Cancer Drug in India - EquityPandit
Pharma stock jumps 12% after it receives nod to import drugs for cancer and tumors - Trade Brains
AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12% - Business Standard
AstraZeneca stock surges over 8% – Check out the reason behind it - Business Upturn
AstraZeneca Pharma India gains on import nod for cancer drug - XM
Astec Lifesciences: Brokerage revises stock's rating post CEO exitDetails - ET Now
AstraZeneca Pharma shares jump 12% to 52-week high on CDSCO permission - Moneycontrol
Aclarion shareholders approve reverse stock split proposal By Investing.com - Investing.com Australia
AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug - Investor's Business Daily
This Is What Whales Are Betting On Astera Labs - Benzinga
Indian giant swoops to take over Scottish company - HeraldScotland
Will Astera Labs Inc. (ALAB) meet earnings estimates this quarter? - US Post News
AstraZeneca falls Monday, underperforms market - MarketWatch
Poor trial results dash AstraZeneca’s hopes for $1bn cancer drug - The Times
ProShare Advisors LLC Sells 79,195 Shares of AstraZeneca PLC (NASDAQ:AZN) - Defense World
AstraZeneca's experimental drug disappoints in breast cancer survival trial - Reuters
AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial - Investopedia
Summit Trail Advisors LLC Purchases 2,159 Shares of AstraZeneca PLC (NASDAQ:AZN) - Defense World
What is Astrana Health Inc. (ASTH) Stock Return on Shareholders’ Capital? - SETE News
AstraZeneca, Daiichi Sankyo’s ADC Flops in Phase III Breast Cancer on Heels of Lung Cancer Stumble - BioSpace
Ascensos retains Scottish HQ after sale to Firstsource - Daily Business
AstraZeneca breast cancer drug trial fails to extend lives of patients - This is Money
Healthcare stock jumps after it enters in an agreement to set up woman and children hospital By Trade Brains - Investing.com India
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients - Yahoo Finance
Aster enters in an agreement to set up woman and children hospital | Tap to know more | Inshorts - Inshorts
Discovery Capital Management LLC CT Reduces Stake in Astera Labs, Inc. (NASDAQ:ALAB) - Defense World
AstraZeneca and Daiichi Sankyo report data from Phase III breast cancer trial - Clinical Trials Arena
AstraZeneca’s experimental cancer drug shows no significant improvement in overall survival - WHTC
Aster DM Healthcare to Build Rs 220 Crore Women & Children's Hospital in Hyderabad, Shares Trading Flat - EquityPandit
AstraZeneca falls to five-month low on breast cancer trial results By Proactive Investors - Investing.com UK
AstraZeneca PLC (NASDAQ:AZN) Stock Position Lifted by Massachusetts Financial Services Co. MA - Defense World
Healthcare stock jumps after it enters in an agreement to set up woman and children hospital - Trade Brains
Rhumbline Advisers Takes $1.01 Million Position in Astera Labs, Inc. (NASDAQ:ALAB) - Defense World
AstraZeneca drug fails to extend lives of breast cancer patients - Financial Times
AstraZeneca and Daiichi Suffer New Setback With Mixed Breast Cancer Drug Results - BNN Bloomberg
AstraZeneca's TROPION-BREAST01 Trial: Mixed Results Reported - Devdiscourse
Aster DM arm inks lease agreement with Aparna Constructions & Estates - Business Standard
Astral Resources NL (ASX: AAR) – Trading Halt - Investing News Network
AstraZeneca breast cancer drug trial fails to improve overall survival - Vox Markets
AstraZeneca PLC (NASDAQ:AZN) Stock Position Raised by Sei Investments Co. - Defense World
AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Edge Capital Group LLC - Defense World
Aster DM Healthcare Expands into Hyderabad But Stock Seems Overvalued - Investing.com India
Astrana Health Inc Stock (ASTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):